22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › IMMUNOVANT INC. › 2024-2025

IMMUNOVANT INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and IMMUNOVANT INC.’s Form 8-K, filed August 13, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 226Asset managers, any item
  • 1,417Fund votes
  • August 12, 2024Meeting date

Results at a glance

Meeting of August 12, 2024: 5 items on IMMUNOVANT INC.’s Form 8-K, filed August 13, 2024: 2 elected · 2 approved · 1 passed (calculated).

Dissent

Significant dissent: 3 directors (26.3%, 25.6%, 24.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Two Seas Capital LP (13F, 2.2%, as of September 30, 2026)

Explore IMMUNOVANT INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by IMMUNOVANT INC.

These tallies are IMMUNOVANT INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed August 13, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IMMUNOVANT INC. — official shareholder meeting results, meeting held August 12, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Peter Salzmann, M.D., M.B.A. 99,849,994---- 31,897,8116,513,760 76%Passed (calculated)—
Elect Director: George Migausky 98,023,809---- 33,723,9966,513,760 74%Elected—
Elect Director: Douglas Hughes 97,129,496---- 34,618,3096,513,760 74%Elected—
2. Ratification of the Selection of Independent Registered Public Accounting Firm 138,241,62816,7403,197 ---- 99.9%Approved—
3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers 128,494,3103,249,1704,325 --6,513,760 98%Approved—

Source: IMMUNOVANT INC., Form 8-K, filed with the SEC on August 13, 2024 — read the filing on EDGAR.

How asset managers voted at the IMMUNOVANT INC. 2024-2025 meeting

226 asset managers disclosed a vote on at least one IMMUNOVANT INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Douglas Hughes

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 97,129,496WITHHELD: 34,618,309

Prior year: 83.1% for (August 21, 2023 meeting) ▼ 9.4 pts

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Douglas Hughes”): 97,129,496 for, 34,618,309 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., George Migausky and Douglas Hughes were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 8,395,082 for, 15,738,953 withheld, 2,336,986 abstained.

FORWITHHOLD
FOR: 8,395,082ABSTAIN: 2,336,986WITHHOLD: 15,738,953
Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity00 07,338,989Withhold
Vanguard6,304,6640 00For
State Street2,2020 02,117,777Withhold
T. Rowe Price00 02,114,983Withhold
BlackRock00 1,768,4660Abstain
Capital Group976,2370 00For
TIAA00 0861,221Withhold
ALGER FUNDS00 0496,198Withhold
Charles Schwab448,5020 00For
Aberdeen00 0400,722Withhold
Invesco00 0361,064Withhold
FRANKLIN STRATEGIC SERIES325,2130 00For
Principal00 0268,304Withhold
Victory Capital00 0237,974Withhold
Jackson National99,6990 88,4990Mixed
Dimensional00 0164,319Withhold
Direxion Shares ETF Trust00 0163,407Withhold
Equitable00 0140,918Withhold
Nuveen00 0132,676Withhold
Delaware/Macquarie00 0122,100Withhold
Bridge Builder Trust00 118,4940Abstain
Russell Investments109,6950 00For
QUANTITATIVE MASTER SERIES LLC00 102,3040Abstain
JPMorgan00 88,8710Abstain
FINANCIAL INVESTORS TRUST00 88,3390Abstain

Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).

Elect Director: George Migausky

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 98,023,809WITHHELD: 33,723,996

Prior year: 83.1% for (August 21, 2023 meeting) ▼ 8.7 pts

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: George Migausky

IMMUNOVANT INC.’s own tally for this item (“Elect Director: George Migausky”): 98,023,809 for, 33,723,996 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., George Migausky and Douglas Hughes were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 8,878,064 for, 15,255,971 withheld, 2,336,986 abstained.

FORWITHHOLD
FOR: 8,878,064ABSTAIN: 2,336,986WITHHOLD: 15,255,971
Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity00 07,338,989Withhold
Vanguard6,304,6640 00For
State Street2,2020 02,117,777Withhold
T. Rowe Price00 02,114,983Withhold
BlackRock00 1,768,4660Abstain
Capital Group976,2370 00For
TIAA00 0861,221Withhold
ALGER FUNDS00 0496,198Withhold
Charles Schwab448,5020 00For
Aberdeen00 0400,722Withhold
Invesco361,0640 00For
FRANKLIN STRATEGIC SERIES325,2130 00For
Principal1470 0268,157Withhold
Victory Capital00 0237,974Withhold
Jackson National99,6990 88,4990Mixed
Dimensional00 0164,319Withhold
Direxion Shares ETF Trust00 0163,407Withhold
Equitable00 0140,918Withhold
Nuveen00 0132,676Withhold
Delaware/Macquarie00 0122,100Withhold
Bridge Builder Trust00 118,4940Abstain
Russell Investments109,6950 00For
QUANTITATIVE MASTER SERIES LLC00 102,3040Abstain
JPMorgan00 88,8710Abstain
FINANCIAL INVESTORS TRUST00 88,3390Abstain

Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).

Elect Director: Peter Salzmann, M.D., M.B.A.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD
FOR: 99,849,994WITHHELD: 31,897,811

Prior year: 84.8% for (August 21, 2023 meeting) ▼ 9.0 pts

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Peter Salzmann, M.D., M.B.A.

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Peter Salzmann, M.D., M.B.A.”): 99,849,994 for, 31,897,811 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 7,627,159 for, 18,489,206 withheld, 354,656 abstained.

FORWITHHOLD
FOR: 7,627,159ABSTAIN: 354,656WITHHOLD: 18,489,206
Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity24,8620 07,314,127Withhold
Vanguard00 06,304,664Withhold
State Street2,117,2320 02,747For
T. Rowe Price1,109,3090 01,005,674Mixed
BlackRock1,768,4660 00For
Capital Group976,2370 00For
TIAA00 0861,221Withhold
ALGER FUNDS00 0496,198Withhold
Charles Schwab448,5020 00For
Aberdeen00 0400,722Withhold
Invesco00 0361,064Withhold
FRANKLIN STRATEGIC SERIES325,2130 00For
Principal1470 0268,157Withhold
Victory Capital00 0237,974Withhold
Jackson National99,6990 88,4990Mixed
Dimensional00 0164,319Withhold
Direxion Shares ETF Trust00 0163,407Withhold
Equitable85,2680 055,650Mixed
Nuveen00 0132,676Withhold
Delaware/Macquarie00 0122,100Withhold
Bridge Builder Trust10,0520 108,4420Mixed
Russell Investments109,6950 00For
QUANTITATIVE MASTER SERIES LLC102,3040 00For
JPMorgan88,8710 00For
FINANCIAL INVESTORS TRUST00 88,3390Abstain

Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).

Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 128,494,310AGAINST: 3,249,170

Prior year: 99.3% for (August 21, 2023 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 225 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

IMMUNOVANT INC.’s own tally for this item (“3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers”): 128,494,310 for, 3,249,170 against — passed, per its Form 8-K filed August 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 75 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at IMMUNOVANT INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,338,9890 00For
Vanguard6,304,6640 00For
State Street2,119,539440 00For
T. Rowe Price2,114,9830 00For
BlackRock1,768,4660 00For
Capital Group0976,237 00Against
TIAA861,2210 00For
ALGER FUNDS0496,198 00Against
Charles Schwab448,5020 00For
Aberdeen400,7220 00For
Invesco0361,064 00Against
FRANKLIN STRATEGIC SERIES325,2130 00For
Principal268,3040 00For
Victory Capital237,9740 00For
Jackson National188,1980 00For
Dimensional164,3190 00For
Direxion Shares ETF Trust163,4070 00For
Equitable140,9180 00For
Nuveen132,6760 00For
Delaware/Macquarie122,1000 00For
Bridge Builder Trust118,4940 00For
Russell Investments109,6950 00For
QUANTITATIVE MASTER SERIES LLC102,3040 00For
JPMorgan88,8710 00For
FINANCIAL INVESTORS TRUST88,3390 00For

Fund voting reports, all 75 managers: 24,423,978 for, 1,998,948 against, 2,595 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 172 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at IMMUNOVANT INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,291,4290 00For
State Street3,155,075609 00For
T. Rowe Price2,918,0070 00For
VIKING GLOBAL INVESTORS LP2,317,4020 00For
Deep Track Capital, LP1,981,4900 00For
BlackRock1,805,45911,397 00For
ARMISTICE CAPITAL, LLC1,686,8250 00For
GEODE CAPITAL MANAGEMENT, LLC1,330,5010 00For
Rock Springs Capital Management LP1,167,6940 00For
PICTET ASSET MANAGEMENT SA1,133,7820 00For
Nuveen1,052,4450 00For
Capital Research Global Investors0976,237 00Against
FRANKLIN ADVISERS INC960,2290 00For
Boxer Capital Management, LLC825,0000 00For
Paradigm Biocapital Advisors LP804,7710 00For
Commodore Capital LP750,9900 00For
Logos Global Management LP720,5010 00For
Redmile Group, LLC666,7040 00For
FRED ALGER MANAGEMENT, LLC0612,865 00Against
Invesco0460,304 00Against
Charles Schwab448,5030 00For
Victory Capital402,8160 00For
Aberdeen400,7220 00For
Northern Trust359,0270 00For
PFM Health Sciences, LP349,9150 00For

Institutional-manager reports, all 172 managers: 40,165,606 for, 2,687,602 against, 45,500 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 138,241,628AGAINST: 16,740

Prior year: 100.0% for (August 21, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2025.

IMMUNOVANT INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 138,241,628 for, 16,740 against — passed, per its Form 8-K filed August 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2025, by th…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 26,468,197 for, 229 against, 2,595 abstained.

FOR
FOR: 26,468,197AGAINST: 229ABSTAIN: 2,595
Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independe” at IMMUNOVANT INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,338,9890 00For
Vanguard6,304,6640 00For
State Street2,119,9790 00For
T. Rowe Price2,114,9830 00For
BlackRock1,768,4660 00For
Capital Group976,2370 00For
TIAA861,2210 00For
ALGER FUNDS496,1980 00For
Charles Schwab448,5020 00For
Aberdeen400,7220 00For
Invesco361,0640 00For
FRANKLIN STRATEGIC SERIES325,2130 00For
Principal268,3040 00For
Victory Capital237,9740 00For
Jackson National188,1980 00For
Dimensional164,3190 00For
Direxion Shares ETF Trust163,4070 00For
Equitable140,9180 00For
Nuveen132,6760 00For
Delaware/Macquarie122,1000 00For
Bridge Builder Trust118,4940 00For
Russell Investments109,6950 00For
QUANTITATIVE MASTER SERIES LLC102,3040 00For
JPMorgan88,8710 00For
FINANCIAL INVESTORS TRUST88,3390 00For

Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).

Largest IMMUNOVANT INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 146,195,673 shares outstanding at the time of that meeting.

Fund voting reports: top IMMUNOVANT INC. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 5.02%
2Vanguard 4.31%
3State Street 1.45%
4T. Rowe Price 1.45%
5BlackRock 1.21%
6Capital Group 0.67%
7TIAA 0.59%
8ALGER FUNDS 0.34%
9Charles Schwab 0.31%
10Aberdeen 0.27%
Institutional-manager reports: top IMMUNOVANT INC. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 7.04%
2State Street 2.16%
3T. Rowe Price 2.00%
4VIKING GLOBAL INVESTORS LP 1.59%
5Deep Track Capital, LP 1.36%
6BlackRock 1.24%
7ARMISTICE CAPITAL, LLC 1.15%
8GEODE CAPITAL MANAGEMENT, LLC 0.91%
9Rock Springs Capital Management LP 0.80%
10PICTET ASSET MANAGEMENT SA 0.78%

Reported IMMUNOVANT INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

IMMUNOVANT INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Roivant Sciences Ltd.113,327,007 —Schedule 13D, filed December 12, 2025
FMR (Fidelity)17,241,035 —Form 13F, quarter ended March 31, 2025
FMR LLC17,078,093 —Proxy statement (DEF 14A), proxy filed July 9, 2025
Entities affiliated with Deep Track Capital, LP9,500,000 —Proxy statement (DEF 14A), proxy filed July 9, 2025
Vanguard Group6,936,859 —Form 13F, quarter ended March 31, 2025
BlackRock5,364,222 —Form 13F, quarter ended March 31, 2025
Peter Salzmann, M.D.3,646,913 —Proxy statement (DEF 14A), proxy filed July 9, 2025
State Street3,087,095 —Form 13F, quarter ended March 31, 2025
Frank M. Torti, M.D.1,710,833 —Proxy statement (DEF 14A), proxy filed July 9, 2025
Geode Capital1,672,590 —Form 13F, quarter ended March 31, 2025

Percentages above are of 146,195,673 shares outstanding, as reported by IMMUNOVANT INC. on its Form 10-Q dated June 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At IMMUNOVANT INC.'s shareholder meeting held August 12, 2024, in the 2024-2025 proxy season, 226 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,417 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — IMMUNOVANT INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: IMMUNOVANT INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on August 13, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IMMUNOVANT INC.’s 10-Q dated June 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

IMMUNOVANT INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “IMMUNOVANT (IMVT) 2024 Annual Meeting (2024-2025 season): Vote Results”, https://proxyvotesnow.com/company/immunovant-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.